Valuation: Shield Therapeutics plc

Market Cap 51.89M 68.59M 60.33M 56.88M 97.04M 6.58B 97.8M 683M 264M 3.35B 258M 252M 10.9B P/E 2026 *
323x
P/E 2027 * 6.54x
Enterprise Value 70.34M 92.98M 81.79M 77.1M 132M 8.93B 133M 925M 359M 4.54B 349M 342M 14.78B EV / Sales 2026 *
1.32x
EV / Sales 2027 * 1x
Free-Float
38.25%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Shield Therapeutics plc

1 week+3.19%
Current month-20.49%
1 month+3.19%
3 months-21.77%
6 months-39.75%
Current year-50.76%
1 week 4.6
Extreme 4.6
5
1 month 4.4
Extreme 4.4
6.4
Current year 3.7
Extreme 3.7
12.5
1 year 3.7
Extreme 3.7
12.5
3 years 1.06
Extreme 1.0625
12.85
5 years 1.06
Extreme 1.0625
52
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 24/07/2024
Director of Finance/CFO 50 01/09/2026
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 68 01/02/2016
Chairman 70 18/06/2020
Director/Board Member 59 26/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/14/25 A Free

Chief Executive Officer

1,547,262 0.1485%
2/13/25 A Free

Chief Executive Officer

5,000,000 0.4800%
2/13/25 A Buy

Chief Executive Officer

575,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+3.19%-34.28%-61.20% 68.79M
-0.78%+0.39%+37.36%-5.05% 80.07B
+1.07%+16.45%+611.28%+87.51% 72.7B
-0.07%+2.70%-10.41%-28.96% 60.45B
-1.80%-3.05%-14.24%+26.38% 46.24B
+0.14%+1.58%+3.62%+165.87% 45.97B
-0.31%+3.45%+64.60%-11.14% 33.62B
-1.01%-3.49%+46.34%+109.63% 25.26B
-3.48%+6.06%+6.80%+166.49% 22.95B
-0.82%-2.20%+57.40%+97.29% 15.44B
Average -0.69%+5.36%+76.85%+54.68% 40.28B
Weighted average by Cap. -0.46%+6.70%+125.86%+51.56%

Financials

2026 *2027 *
Net sales 53.48M 70.7M 62.18M 58.62M 100M 6.79B 101M 703M 273M 3.45B 265M 260M 11.24B 69.92M 92.42M 81.29M 76.63M 131M 8.87B 132M 920M 356M 4.52B 347M 339M 14.69B
Net income 258K 341K 300K 283K 482K 32.74M 486K 3.39M 1.31M 16.66M 1.28M 1.25M 54.22M 7.74M 10.24M 9M 8.49M 14.48M 983M 14.59M 102M 39.47M 500M 38.43M 37.6M 1.63B
Net Debt 18.45M 24.39M 21.45M 20.23M 34.51M 2.34B 34.78M 243M 94.05M 1.19B 91.58M 89.59M 3.88B 18M 23.79M 20.93M 19.73M 33.66M 2.28B 33.92M 237M 91.73M 1.16B 89.32M 87.38M 3.78B
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
24/09/26 GBX 4.850 0.00% 2,394,772
23/09/26 GBX 4.850 +2.11% 3,055,597
22/09/26 GBX 4.750 0.00% 728,393
21/09/26 GBX 4.750 +1.06% 594,145
18/09/26 GBX 4.700 0.00% 755,157
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0485GBP
Average target price
0.1667GBP
Spread / Average Target
+243.65%

Annual profits - Rate of surprise